02:08 , Jan 6, 2016 |  BC Extra  |  Company News

Annapurna gains Weill-Cornell gene therapy assets

Annapurna Therapeutics (Paris, France) received an exclusive license from Weill Cornell Medical College to three preclinical-stage gene therapy programs for alpha-1 antitrypsin deficiency (AATD), hereditary angioedema (HAE) and severe allergies. The company, formerly named AAVLife...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
08:00 , Feb 26, 2015 |  BC Innovations  |  Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
08:00 , Feb 5, 2015 |  BC Innovations  |  Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Versant's voyage

Many life science VCs have narrow geographic footprints, but Versant Ventures has instead expanded operations to Canada and Europe, where it believes there are both good research, and untapped opportunities. The firm also is forgoing...
07:00 , Aug 11, 2014 |  BioCentury  |  Emerging Company Profile

AAVLife: Fixing Friedreich's heart

AAVLife S.A.S. is developing an adeno-associated viral vector-based gene therapy that could become the first disease-modifying treatment for Friedreich's ataxia-associated cardiomyopathy. The therapy has the potential to decrease the risk of cardiac events and improve...
07:00 , May 26, 2014 |  BioCentury  |  Finance

More cash for gene therapy

More cash for gene therapy Lysogene S.A.S. became the fifth gene therapy company this year to raise significant venture dollars. Investors in last week's series A round hope the company's lead product will provide better...
07:00 , Apr 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Reversing (heart) failure in Friedreich's ataxia

Heart failure accounts for over half the deaths in patients with Friedreich's ataxia, but no therapies exist to treat this neurodegenerative disease or its associated cardiomyopathy. Now, a team of French researchers has shown that...
07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Frataxin (FXN; FRDA) Mouse studies suggest FXN gene therapy could help prevent or treat heart failure in patients with Friedreich's ataxia. In presymptomatic mouse...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Financial News

AAVLife completes venture financing

AAVLife S.A.S. , Paris, France   Business: Neurology, Gene/Cell therapy   Date completed: 4/15/14   Type: Venture financing   Raised: $12 million   Investors: Versant Ventures ; Inserm Transfert Initiative  ...